Otto Warburg Laboratory, Max Planck Institute for Molecular Genetics, Berlin, Germany ; Department of Biology, Chemistry, and Pharmacy, Free University of Berlin, Berlin, Germany.
PLoS One. 2013 Nov 12;8(11):e80335. doi: 10.1371/journal.pone.0080335. eCollection 2013.
Given the significant increases in the incidence of metabolic diseases, efficient strategies for preventing and treating of these common disorders are urgently needed. This includes the development of phytopharmaceutical products or functional foods to prevent or cure metabolic diseases. Plant extracts from edible biomaterial provide a potential resource of structurally diverse molecules that can synergistically interfere with complex disorders. In this study we describe the safe application of ethanolic chamomile (Matricaria recutita) flowers extract (CFE) for the treatment and prevention of type 2 diabetes and associated disorders. We show in vitro that this extract activates in particular nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) and its isotypes. In a cellular context, in human primary adipocytes CFE administration (300 µg/ml) led to specific expression of target genes of PPARγ, whereas in human hepatocytes CFE-induced we detected expression changes of genes that were regulated by PPARα. In vivo treatment of insulin-resistant high-fat diet (HFD)-fed C57BL/6 mice with CFE (200 mg/kg/d) for 6 weeks considerably reduced insulin resistance, glucose intolerance, plasma triacylglycerol, non-esterified fatty acids (NEFA) and LDL/VLDL cholesterol. Co-feeding of lean C57BL/6 mice a HFD with 200 mg/kg/d CFE for 20 weeks showed effective prevention of fatty liver formation and hepatic inflammation, indicating additionally hepatoprotective effects of the extract. Moreover, CFE treatment did not reveal side effects, which have otherwise been associated with strong synthetic PPAR-targeting molecules, such as weight gain, liver disorders, hemodilution or bone cell turnover. Taken together, modulation of PPARs and other factors by chamomile flowers extract has the potential to prevent or treat type 2 diabetes and related disorders.
鉴于代谢性疾病发病率的显著增加,迫切需要有效的策略来预防和治疗这些常见疾病。这包括开发植物药产品或功能性食品来预防或治疗代谢性疾病。来自食用生物材料的植物提取物提供了一种具有潜在结构多样性分子的资源,这些分子可以协同干扰复杂的疾病。在这项研究中,我们描述了安全应用醇提甘菊(Matricaria recutita)花提取物(CFE)来治疗和预防 2 型糖尿病及其相关疾病。我们在体外表明,这种提取物特别激活核受体过氧化物酶体增殖物激活受体 γ(PPARγ)及其同工型。在细胞环境中,在人原代脂肪细胞中,CFE 给药(300μg/ml)导致 PPARγ 的靶基因的特异性表达,而在人肝细胞中,我们检测到 CFE 诱导的 PPARα 调节的基因表达变化。在胰岛素抵抗高脂肪饮食(HFD)喂养的 C57BL/6 小鼠体内,用 CFE(200mg/kg/d)治疗 6 周可显著降低胰岛素抵抗、葡萄糖不耐受、血浆三酰甘油、非酯化脂肪酸(NEFA)和 LDL/VLDL 胆固醇。用 200mg/kg/d CFE 与 HFD 共同喂养瘦 C57BL/6 小鼠 20 周,可有效预防脂肪肝形成和肝炎症,表明提取物具有额外的肝保护作用。此外,CFE 治疗没有显示出副作用,而这些副作用与强的合成 PPAR 靶向分子有关,如体重增加、肝疾病、血液稀释或骨细胞转换。总之,甘菊花提取物对 PPAR 及其他因素的调节有可能预防或治疗 2 型糖尿病及相关疾病。